person · Reporting owner

Conroy Kevin T

Disclosed activity across 8 companies

Tapewire entity: 14500
SEC CIK: 0001306119

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ABBOTT LABORATORIESABT · Entity 2314	Director	September 30, 2026	October 03, 2026
ALIGN TECHNOLOGY INCALGN · Entity 3488	Director	May 20, 2026	May 22, 2026
Adaptive Biotechnologies CorpADPT · Entity 1126	Director	March 06, 2023	March 09, 2023
American Exceptionalism Acquisition Corp. AAEXA · Entity 5376	Director	September 25, 2025	December 30, 2025
SomaLogic, Inc.SLGCW · Entity 95310	Director	September 01, 2021	September 04, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ABBOTT LABORATORIES

Report date September 30, 2026 · Filed October 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Equivalent UnitsSEC Table II · derivative / convertible security	Direct	551	Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-30 · Grant · Acquired 318 · Balance 551 F1: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Filing footnotes · ownership attribution and instrument terms

F1: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock.

F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

ALIGN TECHNOLOGY INC

Report date May 20, 2026 · Filed May 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,553	Reported balance After 2026-05-20 transaction · row 1 1 source row Row 1 · 2026-05-20 · Exercise / conversion · Acquired 1,745 · Balance 3,553
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-20 · Exercise / conversion · Disposed 1,745 · Balance 0 F1: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	1,836	Reported balance After 2026-05-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-20 · Grant · Acquired 1,836 · Balance 1,836 F2: 100% of the RSUs granted on May 20, 2026 will become vested on the earlier of (i) May 20, 2027 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person.

F2: 100% of the RSUs granted on May 20, 2026 will become vested on the earlier of (i) May 20, 2027 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date.

Adaptive Biotechnologies Corp

Report date March 06, 2023 · Filed March 09, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	22,968	Reported balance After 2023-03-06 transaction · row 1 1 source row Row 1 · 2023-03-06 · Grant · Acquired 14,775 · Balance 22,968
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.46 · Expires 2033-03-06	Direct	23,329	Reported balance After 2023-03-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-03-06 · Grant · Acquired 23,329 · Balance 23,329 F1: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates.

American Exceptionalism Acquisition Corp. A

Report date September 25, 2025 · Filed December 30, 2025 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Ordinary SharesSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2025-09-25 · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · Balance Not disclosed F1: As described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-289701), under the heading "Description of Securities - Founder Shares," Class B ordinary shares will automatically convert into Class A ordinary shares on or prior to the tenth anniversary of the Issuer's initial business combination, upon the earlier of (A) the Issuer meeting certain share price performance thresholds following the completion of its initial business combination, and (B) subsequent to the completion of its initial business combination, the date on which a change of control occurs, in each case, on a one-for-one basis, subject to adjustment as provided therein.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-289701), under the heading "Description of Securities - Founder Shares," Class B ordinary shares will automatically convert into Class A ordinary shares on or prior to the tenth anniversary of the Issuer's initial business combination, upon the earlier of (A) the Issuer meeting certain share price performance thresholds following the completion of its initial business combination, and (B) subsequent to the completion of its initial business combination, the date on which a change of control occurs, in each case, on a one-for-one basis, subject to adjustment as provided therein.

SomaLogic, Inc.

Report date September 01, 2021 · Filed September 04, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	25,000	Reported balance After 2021-09-01 transaction · row 1 1 source row Row 1 · 2021-09-01 · Other · Acquired 25,000 · Balance 25,000 F1: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.
Warrants to purchase Class A Common Stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2026-09-01	IndirectBy Conroy Family Foundation, Inc.	166,666	Reported balance After 2021-09-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-09-01 · Grant · Acquired 166,666 · Balance 166,666 F2: Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination. The Conroy Family Foundation, Inc. (the "Conroy Foundation") is the record holder of the Class A Common Stock exercisable upon the issuance of warrants reported herein. Mr. Conroy has voting and investment discretion with respect to the Class A Common Stock held of record by the Conroy Foundation. As such, Mr. Conroy may be deemed to have or share beneficial ownership of the securities held directly by the Conroy Foundation. Mr. Conroy disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Class B Common StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-09-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-09-01 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F2: Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination. The Conroy Family Foundation, Inc. (the "Conroy Foundation") is the record holder of the Class A Common Stock exercisable upon the issuance of warrants reported herein. Mr. Conroy has voting and investment discretion with respect to the Class A Common Stock held of record by the Conroy Foundation. As such, Mr. Conroy may be deemed to have or share beneficial ownership of the securities held directly by the Conroy Foundation. Mr. Conroy disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARYA SCIENCES ACQUISITION CORP.

Report date July 01, 2020 · Filed July 07, 2020

Section 16 reporting ended · disclosed 2020-07-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Ordinary SharesSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-07-01 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities.

EXACT SCIENCES CORP

Report date March 23, 2026 · Filed March 23, 2026

Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2026-03-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-03-23 · Grant · Acquired 119,312 · Balance 1,397,738 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding. Row 2 · 2026-03-23 · Disposition to issuer · Disposed 1,397,738 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Common StockSEC Table I · non-derivative	IndirectHeld in 401(k) Plan	Reported balance After 2026-03-23 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-03-23 · Disposition to issuer · Disposed 29,061 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Common StockSEC Table I · non-derivative	IndirectHeld in Grantor Retained Annuity Trust	Reported balance After 2026-03-23 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-03-23 · Disposition to issuer · Disposed 46,538 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Common StockSEC Table I · non-derivative	IndirectHeld in Grantor Retained Annuity Trust	Reported balance After 2026-03-23 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2026-03-23 · Disposition to issuer · Disposed 86,750 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Common StockSEC Table I · non-derivative	IndirectHeld in Grantor Retained Annuity Trust	Reported balance After 2026-03-23 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2026-03-23 · Disposition to issuer · Disposed 117,427 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.68	Direct	Reported balance After 2026-03-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-03-23 · Disposition to issuer · Disposed 235,388 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F4: These options became exercisable in full on February 23, 2021.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.37	Direct	Reported balance After 2026-03-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-03-23 · Disposition to issuer · Disposed 66,047 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F8: These options became exercisable on February 27, 2022.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $92.62	Direct	Reported balance After 2026-03-23 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-03-23 · Disposition to issuer · Disposed 34,110 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F9: These options became exercisable on February 26, 2023.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.18	Direct	Reported balance After 2026-03-23 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-03-23 · Disposition to issuer · Disposed 100,916 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F10: These options became exercisable on February 14, 2024.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-03-23 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-03-23 · Disposition to issuer · Disposed 18,143 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F15: These RSUs vest in four equal annual installments beginning on February 28, 2024.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-03-23 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-03-23 · Disposition to issuer · Disposed 44,336 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F11: These RSUs vest in four equal annual installments beginning on February 28, 2025.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-03-23 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-03-23 · Disposition to issuer · Disposed 83,360 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F12: These RSUs vest in four equal annual installments beginning on February 27, 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-03-23 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-03-23 · Disposition to issuer · Disposed 154,829 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F14: At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time. F13: These RSUs vest in four equal annual installments beginning on February 25, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.

F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding.

F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.

F4: These options became exercisable in full on February 23, 2021.

F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding

F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.

F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding.

F8: These options became exercisable on February 27, 2022.

F9: These options became exercisable on February 26, 2023.

F10: These options became exercisable on February 14, 2024.

F11: These RSUs vest in four equal annual installments beginning on February 28, 2025.

F12: These RSUs vest in four equal annual installments beginning on February 27, 2026.

F13: These RSUs vest in four equal annual installments beginning on February 25, 2027.

F14: At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.

F15: These RSUs vest in four equal annual installments beginning on February 28, 2024.

Epizyme, Inc.

Report date August 12, 2022 · Filed August 16, 2022

Section 16 reporting ended · disclosed 2022-08-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001SEC Table I · non-derivative	Direct	0	Ending reported balance After 2022-08-12 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-08-12 · Disposition to issuer · Disposed 53,324 · Balance 8,994 F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. Row 2 · 2022-08-12 · Disposition to issuer · Disposed 8,994 · Balance 0 F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.

F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 01, 2021 Filed Jul 6, 2021 16:01 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	7,784	$123.43	$960,779.12	Disclosure SEC source: 0001209191-21-045396 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737,328 F1 · security: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 828,999 shares, Mr. Conroy also holds, in the aggregate, an additional 1,207,918 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
June 30, 2021 Filed Jul 1, 2021 20:15 UTC	Epizyme, Inc. EPZM · Entity 12703	GrantCommon Stock, par value $0.0001	1,805	$8.31	$14,999.55	Disclosure SEC source: 0000899243-21-026956 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,147 F1 · shares: The shares were issued to the Reporting Person pursuant to his election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $15,000 for Board services for the second fiscal quarter of 2021. The shares were issued on the last day of the second fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter. Read SEC document
June 11, 2021 Filed Jun 15, 2021 20:35 UTC	Epizyme, Inc. EPZM · Entity 12703	GrantStock Option (Right to Buy) · Derivative	40,559	$0.00 Strike: $8.53	$0.00	Disclosure SEC source: 0000899243-21-023869 · doc4.xml · derivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,559 Underlying: Common Stock · 40,559 shares Expires 2031-06-10 F2 · derivative.exercise_date: This option was granted on June 11, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full. Read SEC document
June 11, 2021 Filed Jun 15, 2021 20:35 UTC	Epizyme, Inc. EPZM · Entity 12703	GrantCommon Stock, par value $0.0001	8,060	$0.00	$0.00	Disclosure SEC source: 0000899243-21-023869 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,342 F1 · shares: Consists of shares of Common Stock issuable under 8,060 restricted stock units ("RSUs") granted on June 11, 2021, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full. Read SEC document
June 01, 2021 Filed Jun 3, 2021 16:11 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	12,384	$111.00	$1,374,624.00	Disclosure SEC source: 0001209191-21-037623 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 745,112 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 836,776 shares, Mr. Conroy also holds, in the aggregate, an additional 1,207,918 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
May 03, 2021 Filed May 5, 2021 16:49 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	19,240	$131.09	$2,522,171.60	Disclosure SEC source: 0001209191-21-030360 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 757,496 F2 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 849,150 shares, Mr. Conroy also holds, in the aggregate, an additional 1,207,918 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
April 30, 2021 Filed May 5, 2021 16:49 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	328	$64.74	$21,234.72	Disclosure SEC source: 0001209191-21-030360 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776,736 F1 · shares: Represents shares of common stock purchased through Employee Stock Purchase Plan. Read SEC document
April 01, 2021 Filed Apr 5, 2021 16:54 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	22,755	$132.30	$3,010,486.50	Disclosure SEC source: 0001209191-21-025188 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776,408 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 868,052 shares, Mr. Conroy also holds, in the aggregate, an additional 1,207,918 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
March 31, 2021 Filed Apr 1, 2021 23:00 UTC	Epizyme, Inc. EPZM · Entity 12703	GrantCommon Stock, par value $0.0001	1,723	$8.71	$15,007.33	Disclosure SEC source: 0000899243-21-014420 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,282 F1 · security: The shares were issued to the Reporting Person pursuant to his election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $15,000 for Board services for the first fiscal quarter of 2021. The shares were issued on the last day of the first fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter. Read SEC document
March 02, 2021 Filed Mar 3, 2021 20:28 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	9,796	$138.42	$1,355,962.32	Disclosure SEC source: 0001209191-21-017506 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 799,163 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on March 1, 2021. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 890,677 shares, Mr. Conroy also holds, in the aggregate, an additional 1,207,918 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
March 01, 2021 Filed Mar 2, 2021 18:56 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	26,958	$136.79	$3,687,584.82	Disclosure SEC source: 0001209191-21-016470 · doc4.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788,384 F3 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F4 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 879,898 shares, Mr. Conroy also holds, in the aggregate, an additional 1,228,493 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
March 01, 2021 Filed Mar 2, 2021 18:56 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	4,335	$137.44	$595,802.40	Disclosure SEC source: 0001209191-21-016470 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 815,342 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 26, 2021. Read SEC document
March 01, 2021 Filed Mar 3, 2021 20:28 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	20,575	$0.00	$0.00	Disclosure SEC source: 0001209191-21-017506 · doc4.xml · derivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,575 Underlying: Common Stock · 20,575 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on February 27, 2018 that partially vested on March 1, 2021. The restricted stock units vest in four equal annual installments beginning on February 27, 2019. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on February 27, 2018 that partially vested on March 1, 2021. The restricted stock units vest in four equal annual installments beginning on February 27, 2019. Read SEC document
March 01, 2021 Filed Mar 3, 2021 20:28 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	20,575	$0.00	$0.00	Disclosure SEC source: 0001209191-21-017506 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 808,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 26, 2021 Filed Mar 2, 2021 18:56 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	9,312	$0.00	$0.00	Disclosure SEC source: 0001209191-21-016470 · doc4.xml · derivative · entry 8 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,624 Underlying: Common Stock · 9,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Represents a restricted stock unit award granted on February 26, 2019 that partially vested on February 26, 2021. The restricted stock units vest in four equal annual installments beginning on February 26, 2020. F6 · derivative.expiration_date: Represents a restricted stock unit award granted on February 26, 2019 that partially vested on February 26, 2021. The restricted stock units vest in four equal annual installments beginning on February 26, 2020. Read SEC document
February 26, 2021 Filed Mar 2, 2021 18:56 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	9,312	$0.00	$0.00	Disclosure SEC source: 0001209191-21-016470 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 819,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 24, 2021 Filed Feb 25, 2021 19:22 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	16,420	$136.30	$2,238,046.00	Disclosure SEC source: 0001209191-21-014492 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,365 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 23, 2021. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 901,879 shares, Mr. Conroy also holds, in the aggregate, an additional 1,237,805 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 23, 2021 Filed Feb 25, 2021 19:22 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	34,325	$0.00	$0.00	Disclosure SEC source: 0001209191-21-014492 · doc4.xml · derivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 23, 2021. The restricted stock units vest in four equal annual installments beginning on February 23, 2018. F5 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 23, 2021. The restricted stock units vest in four equal annual installments beginning on February 23, 2018. Read SEC document
February 23, 2021 Filed Feb 25, 2021 19:22 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	34,325	$0.00	$0.00	Disclosure SEC source: 0001209191-21-014492 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 19, 2021 Filed Feb 23, 2021 18:39 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantRestricted Stock Units · Derivative	41,495	$0.00	$0.00	Disclosure SEC source: 0001209191-21-013403 · doc4.xml · derivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,495 Underlying: Common Stock · 41,495 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
February 17, 2021 Filed Feb 18, 2021 19:27 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	15,825	$142.66	$2,257,594.50	Disclosure SEC source: 0001209191-21-012157 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 792,460 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 16, 2021. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 883,968 shares, Mr. Conroy also holds, in the aggregate, an additional 1,230,635 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 16, 2021 Filed Feb 18, 2021 19:27 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	31,132	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012157 · doc4.xml · derivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,398 Underlying: Common Stock · 31,132 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 16, 2021. The restricted stock units vest in four equal annual installments beginning on February 16, 2021. F5 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 16, 2021. The restricted stock units vest in four equal annual installments beginning on February 16, 2021. Read SEC document
February 16, 2021 Filed Feb 18, 2021 19:27 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	31,132	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012157 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 808,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 14, 2021 Filed Feb 18, 2021 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	GrantStock Option (Right to Buy) · Derivative	3,759	$0.00 Strike: $66.50	$0.00	Disclosure SEC source: 0001209191-21-011550 · doc4.xml · derivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,759 Underlying: Common Stock · 3,759 shares Expires 2031-02-14 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document
February 14, 2021 Filed Feb 18, 2021 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	GrantCommon Stock	1,504	$0.00	$0.00	Disclosure SEC source: 0001209191-21-011550 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 Read SEC document
February 05, 2021 Filed Feb 9, 2021 16:34 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionStock Option (right to buy) · Derivative	17,543	$0.00 Strike: $5.70	$0.00	Disclosure SEC source: 0001209191-21-008825 · doc4.xml · derivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,757 Underlying: Common Stock · 17,543 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options vested and became exercisable in four equal annual installments beginning on February 26, 2017. Read SEC document
February 05, 2021 Filed Feb 9, 2021 16:34 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	17,543	$5.70	$99,995.10	Disclosure SEC source: 0001209191-21-008825 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 777,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 868,657 shares, Mr. Conroy also holds, in the aggregate, an additional 1,261,767 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 01, 2021 Filed Feb 3, 2021 16:20 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	30,344	$138.07	$4,189,596.08	Disclosure SEC source: 0001209191-21-007236 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 759,610 F2 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 851,114 shares, Mr. Conroy also holds, in the aggregate, an additional 1,279,310 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
January 04, 2021 Filed Jan 7, 2021 09:05 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	31,814	$128.74	$4,095,734.36	Disclosure SEC source: 0001209191-21-002431 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 825,704 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 917,198 shares, Mr. Conroy also holds, in the aggregate, an additional 1,279,310 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
December 31, 2020 Filed Jan 5, 2021 13:32 UTC	Epizyme, Inc. EPZM · Entity 12703	GrantCommon Stock, par value $0.0001	1,024	$10.86	$11,120.64	Disclosure SEC source: 0000899243-21-000274 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,559 F1 · security: The shares were issued to the Reporting Person pursuant to his election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $11,125 for Board services for the fourth fiscal quarter of 2020. The shares were issued on the last day of the fourth fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter. Read SEC document
December 28, 2020 Filed Feb 3, 2021 16:20 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GiftCommon Stock	35,750	$0.00	$0.00	Disclosure SEC source: 0001209191-21-007236 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 789,954 F1 · shares: Bona fide gift to Conroy Family Foundation. Read SEC document
December 01, 2020 Filed Dec 2, 2020 18:28 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	100	$126.59	$12,659.00	Disclosure SEC source: 0001209191-20-061271 · doc4.xml · nonDerivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 857,518 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F7 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 949,012 shares, Mr. Conroy also holds, in the aggregate, an additional 1,279,310 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
December 01, 2020 Filed Dec 2, 2020 18:28 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	100	$126.49	$12,649.00	Disclosure SEC source: 0001209191-20-061271 · doc4.xml · nonDerivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 857,618 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. Read SEC document
December 01, 2020 Filed Dec 2, 2020 18:28 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	7,043	$125.92	$886,854.56	Disclosure SEC source: 0001209191-20-061271 · doc4.xml · nonDerivative · entry 5 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 857,718 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.47 to $126.31, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
December 01, 2020 Filed Dec 2, 2020 18:28 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	10,840	$124.88	$1,353,699.20	Disclosure SEC source: 0001209191-20-061271 · doc4.xml · nonDerivative · entry 4 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 864,761 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.44 to $125.43, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
December 01, 2020 Filed Dec 2, 2020 18:28 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	7,776	$124.03	$964,457.28	Disclosure SEC source: 0001209191-20-061271 · doc4.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,601 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.43 to $124.42, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
December 01, 2020 Filed Dec 2, 2020 18:28 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	2,918	$122.91	$358,651.38	Disclosure SEC source: 0001209191-20-061271 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 883,377 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.43 to $123.40, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
December 01, 2020 Filed Dec 2, 2020 18:28 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,800	$122.05	$219,690.00	Disclosure SEC source: 0001209191-20-061271 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886,295 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.42 to $122.38, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
November 02, 2020 Filed Nov 3, 2020 16:49 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	400	$124.71	$49,884.00	Disclosure SEC source: 0001209191-20-056658 · doc4.xml · nonDerivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888,095 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.36 to $125.02, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. F9 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 979,589 shares, Mr. Conroy also holds, in the aggregate, an additional 1,279,310 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
November 02, 2020 Filed Nov 3, 2020 16:49 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	600	$123.45	$74,070.00	Disclosure SEC source: 0001209191-20-056658 · doc4.xml · nonDerivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888,495 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.18 to $123.78, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
November 02, 2020 Filed Nov 3, 2020 16:49 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	9,577	$122.33	$1,171,554.41	Disclosure SEC source: 0001209191-20-056658 · doc4.xml · nonDerivative · entry 5 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 889,095 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.92 to $122.91, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
November 02, 2020 Filed Nov 3, 2020 16:49 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	10,229	$121.52	$1,243,028.08	Disclosure SEC source: 0001209191-20-056658 · doc4.xml · nonDerivative · entry 4 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 898,672 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.92 to $121.91, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
November 02, 2020 Filed Nov 3, 2020 16:49 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	6,512	$120.45	$784,370.40	Disclosure SEC source: 0001209191-20-056658 · doc4.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908,901 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.87 to $120.86, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
November 02, 2020 Filed Nov 3, 2020 16:49 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,108	$119.18	$132,051.44	Disclosure SEC source: 0001209191-20-056658 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 915,413 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.81 to $119.67, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
November 02, 2020 Filed Nov 3, 2020 16:49 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	4,393	$118.32	$519,779.76	Disclosure SEC source: 0001209191-20-056658 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 916,521 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.81 to $118.69, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
October 26, 2020 Filed Apr 29, 2025 16:09 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GiftCommon Stock	163,000	$0.00	$0.00	Disclosure SEC source: 0000950170-25-060116 · ownership.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,120 F1 · balance_after: In addition to the shares of Common Stock reported on this Form 5, which total 628,425 shares, Mr. Conroy also held, in the aggregate, an additional 1,279,310 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
October 01, 2020 Filed Oct 2, 2020 17:54 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,136	$105.20	$119,507.20	Disclosure SEC source: 0001209191-20-053312 · doc4.xml · nonDerivative · entry 4 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,914 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.16 to $105.31, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. F6 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,012,408 shares, Mr. Conroy also holds, in the aggregate, an additional 1,279,310 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
October 01, 2020 Filed Oct 2, 2020 17:54 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	5,200	$104.70	$544,440.00	Disclosure SEC source: 0001209191-20-053312 · doc4.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 922,050 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.16 to $105.14, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
October 01, 2020 Filed Oct 2, 2020 17:54 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	9,391	$103.57	$972,625.87	Disclosure SEC source: 0001209191-20-053312 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 927,250 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.16 to $104.15, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
October 01, 2020 Filed Oct 2, 2020 17:54 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	11,698	$102.86	$1,203,256.28	Disclosure SEC source: 0001209191-20-053312 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 936,641 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.16 to $103.15, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.